Merck & Co., Inc. with ticker code (MRK) have now 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $155.00 and $115.00 with the average share target price sitting at $137.24. (at the time of writing). Given that the stocks previous close was at $105.88 this would imply there is now a potential upside of 29.6%. The day 50 moving average is $113.43 and the 200 moving average now moves to $122.47. The market capitalization for the company is 269.65B. The price for the stock stands currently at: $103.98 USD
The potential market cap would be $349,520,532,299 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 19.26, revenue per share of $24.65 and a 11.38% return on assets.
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services for the prevention, treatment and control of disease in all major livestock and companion animal species.
